# Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Source: https://onco.cc/trials/nct05623267/  
OnCo record `nct05623267` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of sugemalimab in lung cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT is a phase 2/3, randomised interventional study registered as NCT05623267 by Sun Yat-sen University, with a registry enrolment figure of 346 participants, started 2023-07-01 and due to reach its primary completion in 2025-12-31. Interventions recorded: Sugemalimab; Placebo. Conditions listed: Limited Stage Small Cell Lung Cancer. Primary outcome: Progress Free Survival(PFS). Lung eligibility wording from the registry: "2、Histologically or cytologically confirmed small cell lung cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: SURPASS
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05623267
- Phase: 2/3
- Setting: A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy
- Sponsor: Sun Yat-sen University
- Enrolled: 346

## Sources

- ClinicalTrials.gov NCT05623267: https://clinicaltrials.gov/study/NCT05623267

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- drugs: [Sugemalimab](https://onco.cc/drugs/sugemalimab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05623267.json